SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Protein Design Labs (PDLI): Stock strong
An SI Board Since February 1997
Posts SubjectMarks Bans Symbol
407 58 0 PDLI
Emcee:  Stanley Cowen Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
357Merrill NDC monthly data for PDL’s products in-line so far in 4Q06 NDC monthly tom pope-12/28/2006
356Form 8-K for PDL BIOPHARMA, INC. 19-Dec-2006 Item 8.01. Other Events. Followinnigel bates-12/19/2006
355Merrill, making same point you were, essentially Roche terminates daclizumab cotom pope-11/22/2006
354Another disappointing news, but PDLI and BIIB continue to develop daclizumab foridos-11/22/2006
353I had a couple of shares left but I am completely out after the news.kenhott-11/22/2006
352PDL BioPharma Announces Roche to Discontinue Co-Development of Daclizumab Tuesdanigel bates-11/21/2006
351Merrill: Strong 3Q Lucentis sales boost 4Q06 royalty estimate Based on Genentectom pope-10/11/2006
350gotcha, and thanks. That explains it. I just have an obsession with the Elan sagtom pope-9/28/2006
349Natrecor is labeled for acute heart failure, basically when the disease puts thekenhott-9/28/2006
348Thank you. I keep on thinking of Elan, and the risk benefit calculation in the wtom pope-9/27/2006
347Natrecor might be withdrawn in the future, but not at this time until more studidr.praveen-9/27/2006
346Is there any possibility Natrecor could be withdrawn?tom pope-9/27/2006
345Natrecor Linked to Early Deaths in Acute Decompensated Heart Failure By Neil Osdr.praveen-9/27/2006
344Hi Tom, It doesn't look so black and white. PDLI's 2 main drugs aiming dr.praveen-9/24/2006
343ARNA might learn from them. From Merrill: PDL holding off on Ularitide phase IItom pope-9/22/2006
342PDL Biopharma: Troubled Summer, But Holding On Wednesday September 13, 3:44 pm Edr.praveen-9/13/2006
341Citigroup from August 30, 2006: "We had not included any revenue projectioidos-9/4/2006
340Merrill: Roche discontinues daclizumab co-development in asthma PDL announced ttom pope-8/30/2006
339PDL BioPharma Announces Roche Discontinuation of Co-Development of Daclizumab inIRWIN JAMES FRANKEL-8/30/2006
33808:31 PDLI PDL BioPharma announces Roche discontinuation of co-development of IRWIN JAMES FRANKEL-8/30/2006
337PDL BioPharma Adopts Stockholder Rights Plan Monday August 28, 8:30 am ET FREMOnigel bates-8/28/2006
336This is from the lastest PDLI 10Q: Our humanization patents are being opposed akenhott-8/22/2006
335I have a small position in PDLI based primarily on their IP generated royalty stfred hayes-8/21/2006
334"Crazy" reminds me of a Boz Scaggs song. Simply can't hear it tooscaram(o)uche-8/18/2006
333Mesavance isn't really competition, it's the first long acting sulfa drurkrw-8/13/2006
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News